Navigation Links
Website for new open-access journal, eLife, introduced today
Date:12/13/2012

CAMBRIDGE, UK | December 13, 2012 -- eLife, the open-access journal for outstanding advances in life science and biomedicine, reveals a fresh approach to presenting and using scientific content on its new website, launched today.

In June 2011, three leading research funders came together in a unique collaboration to inspire change in science communication. The first product of this partnership is eLife an open-access journal for the most influential research in life science and biomedicine. After much anticipation surrounding the announcement of the project, recruitment of the academic editorial team, the call for papers, and the publication of first articles, the eLife journal website is introduced today.

The eLife journal invites visitors to explore important new research and associated data, read comments and commentary by experts and colleagues, and get a sense of the quality of work that eLife is publishing.

Nineteen research papers have now been selected for publication by eLife's academic editors. "eLife editors have successfully established a high bar for the journal," said Randy Schekman, Editor-in-chief. "We will continue to publish only those papers deemed highly influential or important. Authors who give us a try will be rewarded with a quick initial decision and for those selected for full peer review a constructive and decisive review process. Feedback has been very positive, with board members, referees, and authors all embracing our approach."

The new site also offers a chance to explore how eLife is taking advantage of digital media. Presentation of content is clean and distraction-free, allowing authors to present the results of their research in full, and inviting readers to delve deeply into the work by exploring figures and their supplements, watching videos, reading editor decision le
'/>"/>

Contact: Jennifer McLennan
j.mclennan@elifesciences.org
301-215-8938
eLife
Source:Eurekalert

Page: 1 2

Related biology news :

1. Revealing climate change website wins global award
2. NIST launches new website to educate industry about alternatives to mercury thermometers
3. Wiley-Blackwell launches new open-access journal: Food Science & Nutrition
4. Chemicals today, drugs tomorrow: U-Ms new Center for Drug Discovery
5. NJIT professor awarded patent today for new desalination devices, more
6. Oceans acidifying faster today than in past 300 million years
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2015)... New Market Research Reports Title ... To 2020 has Been Added to GrandViewReseach.com Report Database ... to reach USD 5.10 billion by 2020, according to ... cameras help identify the site of tissue damage in ... demand in medical imaging applications. They have been extensively ...
(Date:2/5/2015)... , Feb. 3, 2015 Despite ... demand from industries such as consumer electronics, automotive, ... for surface mount technology (SMT) screen printers. Innovations ... automatic control will push the adoption curve up. ... remain steady as glue dispensers are indispensable in ...
(Date:1/22/2015)... 2015  Today, FreeWavz ( www.FreeWavz.com ), the developer ... on Fundable, https://www.fundable.com/freewavz . FreeWavz will be ... to meet customer demand. Logo - ... Invented by Dr. ...
Breaking Biology News(10 mins):IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 2IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 3End-user Demand Spurs Global SMT Screen Printers and Glue Dispensers Market 2End-user Demand Spurs Global SMT Screen Printers and Glue Dispensers Market 3FreeWavz Launches on Fundable to Drive Speed-to-Market in 2015 2
... rate of incidence and mortality-the number of those who get ... Multiforme (GBM) is a brain cancer death sentence. , Of ... in the U.S., half will die within a year, and ... stretch survival limits are exceptionally invasive surgeries to remove the ...
... vessels within the tissue of previously engineered heart muscle. ... function. The study is published in the journal ... individuals globally and contributing to increasing mortality rates, there ... One of the specific challenges in the field ...
... whales emit their characteristic calls remains largely a ... sounds provides a valuable way to track the ... devices equipped with hydrophones (underwater microphones), deployed in ... recent years to track seasonal occurrences of blue, ...
Cached Biology News:Radiotherapy advance points way to noninvasive brain cancer treatment 2Radiotherapy advance points way to noninvasive brain cancer treatment 3Underwater listening devices yield discoveries about endangered large whales 2
(Date:3/4/2015)... 4, 2015  Brooklyn residents now have a new ... pain and injuries. Nunzio Saulle , M.D., a ... of his NJS Physical Medicine and Rehabilitation (PM&R) practice ... March 5, 2015. Health Plus Management, LLC is managing ... at 1178 Flatbush Avenue. This new PM&R practice will ...
(Date:3/4/2015)... /CNW/ - Resverlogix Corp. (TSX:RVX) (the "Company") today ... research program with Emerald Logic, a leader ... Technology (FACET), Emerald Logic analyzed Resverlogix,s complete ... each of 798 patients who participated in ... SUSTAIN and ASSURE. The objective of this ...
(Date:3/4/2015)... Pa. , March 4, 2015 /PRNewswire/ ... services and technology provider, today announced that ... 10 countries convened at its annual European ... to discuss the use of ... challenges. BioClinica,s eClinical technologies include: the Microsoft ...
(Date:3/4/2015)... Lancée par l,Assistance ... en décembre 2011, l,étude collaborative française randomisée ... compare   l es microsphères en résine ... le carcinome hépatocellulaire avancé, a recruté plus de ...   ; les résultats sont attendus fin 2016. ...
Breaking Biology Technology:NJS Physical Medicine & Rehabilitation Opening on Flatbush Avenue, Brooklyn, NY 2Resverlogix Collaborates with Emerald Logic to Identify Factors Driving Drug Response and Efficacy in Phase 2 Program 2Resverlogix Collaborates with Emerald Logic to Identify Factors Driving Drug Response and Efficacy in Phase 2 Program 3Resverlogix Collaborates with Emerald Logic to Identify Factors Driving Drug Response and Efficacy in Phase 2 Program 4BioClinica Teams With Pharma To Tackle Clinical Trial Challenges In Europe 2BioClinica Teams With Pharma To Tackle Clinical Trial Challenges In Europe 3Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 2Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 3Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 4Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 5Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 6
... THE WOODLANDS, Texas, June 17 ... an Orphan Product Development Grant by the FDA,to support ... Pediatric Ventricular Assist Device (VAD). Dr. Christopher Almond of,the ... of,Clinical Affairs for Berlin Heart Inc. will serve as ...
... for liquid culture tests will accelerate access to improved ... BD (Becton, Dickinson and Company; NYSE: BDX ... (Foundation for Innovative New Diagnostics), a Swiss foundation that ... tools for poverty-related diseases, today announced a significant price ...
... OSLO, Norway, June 17 , ... to Improve Remission Rates and,Reduce Short-Term Mortality Compared to ... ASA (OSE: CLAVIS) today announces positive final results,from a ... elacytarabine,(CP-4055), in patients with late-stage acute myeloid leukaemia (AML). ...
Cached Biology Technology:Berlin Heart Inc. Receives FDA Orphan Product Development Grant 2BD and FIND Achieve Milestone in Global Battle Against MDR-TB 2BD and FIND Achieve Milestone in Global Battle Against MDR-TB 3BD and FIND Achieve Milestone in Global Battle Against MDR-TB 4Phase II Trial Demonstrates Elacytarabine May Increase Survival Threefold in Patients With Late-Stage Leukaemia 2Phase II Trial Demonstrates Elacytarabine May Increase Survival Threefold in Patients With Late-Stage Leukaemia 3Phase II Trial Demonstrates Elacytarabine May Increase Survival Threefold in Patients With Late-Stage Leukaemia 4Phase II Trial Demonstrates Elacytarabine May Increase Survival Threefold in Patients With Late-Stage Leukaemia 5Phase II Trial Demonstrates Elacytarabine May Increase Survival Threefold in Patients With Late-Stage Leukaemia 6Phase II Trial Demonstrates Elacytarabine May Increase Survival Threefold in Patients With Late-Stage Leukaemia 7
... Ambions MAXIscript In Vitro Transcription Kits ... 1 x 10 9 cpm/g. High ... in ribonuclease protection assays, in situ hybridization, ... be used for the synthesis of modest ...
Mouse H60 Allophycocyanin MAb (Clone 205326) ENTREZ GeneID: 15101...
... 250 ul (125 precipitations). ... easy pellet location.Efficient precipitation ... inert, compatible with most ... protocol. Category: DNA/RNA Synthesis ...
... for monitoring Aldolase tests. 2 levels ... targeted manufacturing values at 4 ± ... IU/L. 30-day shelf life once ... Level 1: 3 x 3 ml; ...
Biology Products: